CHI member Bayer Healthcare recently announced that its has received approval from the U.S. Food and Drug Administration to begin marketing a new therapy for patients with prostate cancer. The new treatment, Xofigo, is the second prostate cancer therapy ever to be approved by the FDA. It is intended for patients with castration-resistant prostate cancer [...]
and Innovation
CHI-California Healthcare Institute represents more than 275 leading biotechnology, diagnostics, medical device and pharmaceutical companies and public and private academic biomedical research organizations.